Several third generation EGFR TKIs which are EGFR mutant selective and wild-type (WT) sparing were developed to treat these patients with T790 M acquired resistant mutation. Osimertinib is one of the third generation EGFR TKIs and is currently the …

Rezivertinib is a third-generation EGFR TKI with great development potential in the future. The NCT03866499 trial is a randomized, double-blind, phase 3 trial that evaluated the efficacy and safety of rezivertinib compared with gefitinib as a first-line treatment in NSCLC patients with advanced EGFR mutations.

May 9, 2022 · In this Review, we discuss the development of third-generation EGFR and ALK inhibitors, predominant mechanisms of resistance, and approaches to tackling resistance in the clinic, ranging from...

May 1, 2021 · The emergence of the acquired EGFR gatekeeper T790M mutation after first- or second-generation EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant (EGFR+) NSCLC has necessitated the development of third-generation EGFR TKIs to overcome this frequently acquired mutation.

Targeted therapy with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) is a standard modality of the 1st-line treatments for patients with advanced EGFR -mutated non-small cell lung cancer (NSCLC), and substantially improves their prognosis.

Dec 7, 2021 · Most patients treated with 1st or 2nd generation TKI’s will eventually develop resistance to treatment. 2 Third generation TKI’s offer new hopes for patients with progressive NSCLC. The most important mechanism of acquired resistance to these drugs is the EGFR T790M mutation.

The present article provides a review of the development process, mechanism of action and clinical trials of the third‑generation EGFR‑TKIs, aiming to provide some reference and suggestions for the clinical treatment of NSCLC and scientific research on …

Osimertinib was the first third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to receive FDA and EMA approval for metastatic EGFR -mutant non-small-cell lung cancer (NSCLC) patients that have acquired the EGFR T790M resistance mutation.

Feb 19, 2018 · Several third generation EGFR TKIs which are EGFR mutant selective and wild-type (WT) sparing were developed to treat these patients with T790 M acquired resistant mutation. Osimertinib is one of the third generation EGFR TKIs and is currently the most advanced in clinical development.

Feb 15, 2019 · Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M